Docetaxel Secretion in Tears
Association With Lacrimal Drainage Obstruction
Bita Esmaeli, MD;
M. Amir Ahmadi, MD;
Edgardo Rivera, MD;
Vicente Valero, MD;
Toni Hutto, BS;
Denise M. Jackson, RN;
Robert A. Newman, PhD
Arch Ophthalmol. 2002;120:1180-1182.
Objective To test the hypothesis that docetaxel may be secreted in tears after
intravenous infusion.
Design Prospective pilot trial.
Patients and Methods Tear fluid was collected from 4 patients receiving docetaxel weekly
and 2 patients receiving docetaxel every 3 weeks as a single agent for the
treatment of metastatic breast cancer. Tear samples were collected once prior
to and again within 30 minutes following the end of the 1-hour docetaxel infusion.
A blood sample was also obtained after infusion. The tear and plasma samples
were analyzed for drug content using high-performance liquid chromatography
and tandem mass spectrometry.
Results Docetaxel was found in the tear samples collected from all 6 patients.
Conclusion The secretion of docetaxel in tears may be a mechanism for canalicular
inflammation and tear drainage obstruction, which are known to occur as an
adverse effect of the drug.
From the Ophthalmology Section, Department of Plastic Surgery (Drs
Esmaeli and Ahmadi), the Department of Breast Medical Oncology (Drs Rivera
and Valero and Ms Jackson), and the Department of Experimental Therapeutics
(Dr Newman and Ms Hutto), the University of Texas M. D. Anderson Cancer Center,
Houston.
THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES
Imaging Characteristics of Dacryocystocele Diagnosed after Surgery for Sinonasal Cancer
Debnam et al.
Am. J. Neuroradiol. 2007;28:1872-1875.
ABSTRACT
| FULL TEXT
Prospective Study of Incidence and Severity of Epiphora and Canalicular Stenosis in Patients With Metastatic Breast Cancer Receiving Docetaxel
Esmaeli et al.
JCO 2006;24:3619-3622.
ABSTRACT
| FULL TEXT
|
